Home
|
About us
|
Contact us
About AWMSG
All Wales Medicines Strategy Group (AWMSG)
New Medicines Group (NMG)
All Wales Prescribing Advisory Group (AWPAG)
Meetings
Appraisals
Appraisal information
Patients/carers/patient organisations
Healthcare professionals
Pharmaceutical industry
Search and reports
Search and browse
Reports
Medicines management
About
Forthcoming work programme
National prescribing indicators
Clinical effectiveness prescribing programme
Appraisal monitoring
In-patient medication administration record
Patient information leaflets
Library
azithromycin (Zedbac®)
Reference No. 2476
Publication date:
14/08/2014
Last review date:
29/09/2017
Appraisal information
azithromycin (Zedbac®) 500 mg powder for solution for infusion
Company:
Aspire Pharma Ltd
BNF category:
Infections
NMG meeting date:
18/06/2014
AWMSG meeting date:
16/07/2014
Submission Type:
Limited Submission
Status:
Recommended with restrictions
Advice No:
1914
Ratification by Welsh Government:
13/08/2014
Current Progress
Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government
AWMSG advice
Azithromycin (Zedbac®) 500 mg powder for solution for infusion is recommended as an option for restricted use within NHS Wales. Azithromycin (Zedbac®) 500 mg powder for solution for infusion should be restricted for use within NHS Wales for the treatment of community-acquired pneumonia (CAP) due to susceptible microorganisms, in adult patients where initial intravenous therapy is required. Azithromycin (Zedbac®) 500 mg powder for solution for infusion is not recommended for use within NHS Wales for the treatment of pelvic inflammatory disease (PID) due to susceptible microorganisms, in patients where initial intravenous therapy is required.
Final Appraisal Recommendation (FAR)
Download
azithromycin (Zedbac) 2476 FAR
AWMSG Secretariat Appraisal Report (ASAR)
Download
azithromycin (Zedbac) 2476 ASAR
Clinical Expert (CE) Summary
Download
azithromycin (Zedbac) 2476 CE summary